Drug Trial Radar · NCT00717457
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,189
Actual
Start
Jul 2008
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly) or exenatide (5 micrograms twice daily for 4 weeks followed by 10 micrograms twice daily) in a ratio of 1:1:1 in addition to continued prestudy metformin and thiazolidinedione either alone or in combination. The anticipated time on study treatment is 3+ years, and the target sample size is \>500 individuals.
Conditions
- Diabetes Mellitus Type 2
Interventions
exenatideDrug
5mg twice daily for 4 weeks followed by 10mg twice daily
taspoglutideDrug
10mg once weekly
taspoglutideDrug
10mg once weekly for 4 weeks followed by 20mg once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: 24 weeks
Locations
216 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Haleyville, Alabama
Site not named
Mobile, Alabama
Site not named
Montgomery, Alabama
Site not named
Tuscaloosa, Alabama
Site not named
Little Rock, Arkansas
Site not named
Escondido, California
Site not named
La Jolla, California
Site not named
Mission Viejo, California
Site not named
Orange, California
Site not named
Palm Springs, California
Site not named
Rancho Cucamonga, California
Site not named
Sacramento, California
Site not named
San Leandro, California
Site not named
Colorado Springs, Colorado
Site not named
Daytona Beach, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Green Cove Springs, Florida
Site not named
Jacksonville, Florida
Site not named
Miami Beach, Florida
Site not named
Niceville, Florida
Site not named
Orlando, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Suwanee, Georgia
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Lombard, Illinois
Site not named
Peoria, Illinois
Site not named
Evansville, Indiana
Site not named
New Albany, Indiana
Site not named
Iowa City, Iowa
Site not named
Munfordville, Kentucky
Site not named
Metairie, Louisiana
Site not named
Bangor, Maine
Site not named
Baltimore, Maryland
Site not named
Bethesda, Maryland
Site not named
Rockville, Maryland
Site not named
Royal Oak, Michigan
Site not named
Jefferson City, Missouri
Site not named
Kansas City, Missouri
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.